| Oct 31 |
BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program
|
| Oct 10 |
BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events
|
| Oct 3 |
BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
|
| Sep 19 |
BioRestorative Therapies’ IFATS 2024 Presentation to Feature ThermoStem® Platform’s Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs
|
| Aug 14 |
BioRestorative Therapies, Inc. (BRTX) Q2 2024 Earnings Call Transcript
|
| Aug 13 |
Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 13 |
BioRestorative Therapies GAAP EPS of -$0.50 beats by $0.05
|
| Aug 13 |
BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Aug 6 |
BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024
|
| Jul 23 |
BioRestorative Therapies’ Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine
|
